Alternatives to chemotherapy and radiotherapy in the treatment of small cell lung cancer

Seminars in Oncology

Volumn 28, Issue 2 SUPPL. 4, 2001, Pages 30-37

  Shepherd, Frances A ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIIDIOTYPIC ANTIBODY; BMS 248967; GANGLIOSIDE GD3; HEPARIN; INTERFERON; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BEC2; REBIMASTAT; TAMOXIFEN; TUMOR VACCINE; UNCLASSIFIED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL TRIAL; HUMAN; LUNG SMALL CELL CANCER; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0034903228     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0093-7754(01)90076-4     Document Type: Review

References (50)

1. Cancer statistics, 2000
2. Classification, histology, cytology and electron microscopy
3. Staging and prognostic factors for small cell lung cancer
4. Surgical management of small cell lung cancer
5. Treatment of small cell lung cancer: Chemotherapy
6. Chemotherapy for small cell lung cancer
7. The role of chemotherapy in the treatment of small cell lung cancer
8. New drugs in lung cancer
9. A meta-analysis of thoracic radiotherapy for small cell lung cancer
10. Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis
11. Prophylactic cranial irradiation in small cell lung cancer
12. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission
13. Effect of postoperative empyema on survival of patients with bronchogenic carcinoma
14. Postoperative empyema improves survival in lung cancer
15. Natural interferon alfa as maintenance for small cell lung cancer
16. Phase III trial of recombinant interferon gamma in complete responders with small cell lung cancer
17. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small cell lung cancer: A Southwest Oncology Group Study
18. α interferon (alfa-IFN) as maintenance therapy for small cell lung cancer (SCLC)
19. Carbohydrate vaccines that induce antibodies against cancer
20. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases
21. Randomized trial of monoclonal antibody for adjuvant therapy of resected Duke's C colorectal carcinoma
22. Prolonged survival for melanoma patients with elevated IgM antibody to oncofetal protein
23. Antibodies against autologous tumor cell proteins in patients with small-cell lung cancer: Association with improved survival
24. Selection of tumor antigens as targets for immune attack using immunohistochemistry: Focus on gangliosides
25. Biosynthesis and expression of the disialoganglioside GD2, a relative target antigen on small cell lung carcinoma for monoclonal antibody-mediated cytolysis
26. Isolation and characterization of GD3 ganglioside having a novel disialosyl residue from rabbit thymus
27. Induction of IgG antibodies against GD3 in rabbits by an anti-idiotypic monoclonal antibody
28. Immunization of melanoma patients with anti-idiotypic monoclonal antibody BEC-2 (which mimics GD-3 ganglioside): Pilot trials using no immunological adjuvant vaccine research
29. Long term survival following immunization with Bec-2 plus BCG after initial therapy for small cell lung cancer (SCLC)
30. Phase I trial of immunological adjuvant QS-21 with GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma
31. Rationale and experimental design for the VA cooperative study of anticoagulation (Warfarin) in the treatment of cancer
32. Biologic basis for anti-coagulant treatment for cancer
33. A randomized trial of anticoagulation with warfarin and of alternating chemotherapy in extensive small-cell lung cancer by the Cancer and Leukemia Group B
34. Subcutaneous heparin treatment increases survival in small cell lung cancer
35. Anti-coagulants in small cell lung cancer (SCLC): A randomized clinical trial comparing five weeks of heparin at curative dosage versus five months of low molecular weight heparin at preventive dosage
36. No effect of an anti-aggregant treatment with aspirin in small cell lung cancer treated with CCAVP16 chemotherapy. Results from a randomized clinical trial of 303 patients. The "Petites Cellules" Group
37. Matrix metalloproteinase inhibition: A review of anti-cancer agents
38. Mechanisms controlling the transcription of matrix metalloproteinase genes in normal and neoplastic cells
39. Changing views of the role of matrix metalloproteinases in metastasis
40. Characterization of a connective tissue degrading metalloproteinase from human SCLC cells
41. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas
42. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer
43. Autocrine growth factors and lung cancer
44. Insulin-like growth factor-1 can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro
45. Epidermal growth factor-related peptides and their receptors in human malignancies
46. Epidermal growth factor (EGF) expression in non-small cell carcinomas correlates with metastatic involvement of the hilar and mediastinal nodes in the squamous subtype
47. Carcinoembryonic antigen arginine vasopressin and calcitonin as markers of early small-cell lung cancer relapse
48. Biochemical and pharmacological properties of SR 49059, a new potent, non-peptide antagonist of rat and human vasopressin V1a receptors
49. Effect of a new, potent, non-peptide V1a vasopressin antagonist SR 49059 on the binding and mitogenic activity of vasopressin on Swiss 3T3 cells